Current Report Filing (8-k)
November 07 2018 - 4:11PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2018
Achillion Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33095
|
|
52-2113479
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
300 George Street
New Haven, CT
|
|
06511
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (203)
624-7000
N/A
(Former name or former address, if changed since last report)
Check the appropriate box if the Form
8-K
is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12).
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14a-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act
(17 CFR
240.13e-4(c)).
|
Indicate by checkmark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
|
Results of Operations and Financial Condition
|
On November 7, 2018, Achillion Pharmaceuticals, Inc. (the Company) announced its financial results for the fiscal quarter ended
September 30, 2018. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The information in this Form
8-K
(including Exhibit 99.1) shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits
|
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: November 7, 2018
|
|
|
|
ACHILLION PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Mary Kay Fenton
|
|
|
|
|
|
|
Mary Kay Fenton
|
|
|
|
|
|
|
Chief Financial Officer
|
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024